Abstract
This study found that autophagy induction might be the mechanism through which metformin suppressed the growth of AR-negative prostate cancer. Moreover, the activation of AMPK/autophagy pathway might be a therapeutically effective for treating AR-negative prostate cancer in the future.
Introduction
Prostate cancer remains a leading cause of cancer-related mortality. While androgen deprivation therapy is effective for many, a significant subset of patients develops androgen receptor (AR)-negative prostate cancer. These cases are notoriously aggressive, often metastasizing to the bone and lacking effective targeted therapies. This research investigates the potential of repurposing metformin—an FDA-approved medication for Type 2 diabetes—to treat these resistant cancer strains by uncovering its underlying molecular mechanisms.
Experimental Methodology
The researchers utilized human AR-negative prostate cancer cell lines, DU145 and PC3, to evaluate metformin's efficacy. The study employed a multi-tiered approach:
- In Vitro Assays: CCK-8 tests for cell viability, colony formation assays, and flow cytometry for cell cycle analysis.
- Molecular Analysis: siRNA-mediated knockdown of AMPK and pharmacological inhibition of autophagy (using 3-MA) were used to confirm the signaling pathway.
- In Vivo Models: DU145 xenografts in nude mice were treated with oral metformin to observe tumor shrinkage and systemic toxicity.
Results: Suppression of Cancer Cell Growth
Metformin demonstrated a potent ability to inhibit the growth and proliferation of AR-negative prostate cancer cells. In vitro experiments showed that metformin treatment significantly reduced the ability of both DU145 and PC3 cells to form colonies and replicate.
Further analysis revealed that this growth inhibition was both dose- and time-dependent. In DU145 cells, increasing concentrations of metformin (from 1 mM to 20 mM) led to progressively lower cell viability over 24, 48, and 72 hours, with the most significant effects observed at higher concentrations and longer exposure times.
Mechanism: The AMPK/Autophagy Axis
The study identified the AMPK/autophagy signaling pathway as the primary driver of metformin's anti-cancer effects. Metformin activates AMPK (AMP-activated protein kinase), an energy sensor that triggers autophagy—a cellular "self-eating" process. While autophagy can sometimes aid cell survival, its induction by metformin in this context leads to G0/G1 cell cycle arrest, effectively forcing cancer cells into a non-replicative state. This was confirmed by the upregulation of p-AMPK and LC3II (autophagy markers) and the downregulation of growth-related proteins like Cyclin D1 and PCNA.
Conclusion and Future Directions
Metformin shows significant promise as a low-toxicity therapeutic option for aggressive AR-negative prostate cancer. In mouse models, it reduced tumor volume without causing liver or kidney abnormalities. While the concentrations required in vitro exceed typical clinical levels for diabetes, the clear activation of the AMPK/autophagy axis provides a robust molecular target. Future research should focus on optimizing clinical dosages and exploring metformin as a sensitizing agent in combination with existing chemotherapies or radiation to prevent recurrence.
Summary updated